BrainsWay (NASDAQ:BWAY – Get Free Report) is set to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of $0.01 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.
BrainsWay Price Performance
BWAY opened at $10.86 on Friday. The business’s 50-day moving average price is $9.06 and its two-hundred day moving average price is $7.35. BrainsWay has a 1 year low of $3.78 and a 1 year high of $10.89. The company has a market capitalization of $181.14 million, a price-to-earnings ratio of 217.24 and a beta of 1.25.
Analysts Set New Price Targets
A number of analysts recently issued reports on BWAY shares. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of BrainsWay in a research report on Monday, October 21st. Northland Securities increased their price target on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a research report on Thursday, October 3rd.
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Read More
- Five stocks we like better than BrainsWay
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Basic Materials Stocks Investing
- MarketBeat Week in Review – 11/4 – 11/8
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.